More on INTS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Intensity Therapeutics (NQ:INTS)
Delayed: 4.75 -0.15 (3.06%)
Prev. Close $4.90  
Open$4.80 
52 Wk High$ 
52 Wk Low$ 
Day High$4.80 
Day Low$4.57 
P/E N/A  
EPS$ 
Volume19,767 


Jul 15, 2026 07:45 AM Intensity Therapeutics resumes breast cancer trial in Switzerland
Jul 15, 2026 07:45 AM Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Jul 8, 2026 04:01 PM Form S-8 INTENSITY THERAPEUTICS,
Jul 1, 2026 04:09 PM Form 4 INTENSITY THERAPEUTICS, For: Jun 30 Filed by: Wesolowski John M
Jul 1, 2026 04:08 PM Form 4 INTENSITY THERAPEUTICS, For: Jun 30 Filed by: Talamo Joseph
Jul 1, 2026 08:01 AM Intensity Therapeutics resumes clinical trials, pursues partners for INT230-6
Jul 1, 2026 08:00 AM Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
Jun 16, 2026 04:15 PM Form 8-K INTENSITY THERAPEUTICS, For: Jun 16
May 20, 2026 09:37 AM Benchmark Reiterates Speculative Buy Rating on Intensity Therapeutics, Inc. (INTS)
May 14, 2026 08:00 AM Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
View All Articles

Entities mentioned with INTS

View All Entities